Pfizer, Inc. (PFE) Analyst Ratings & Price Targets

Pfizer, Inc.

PFE · NYSE

Analyst Consensus

Hold

20 analysts

$30

Current

$25

Low

$29

Average

$25

High

Average target implies -3.33% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Hold among 20 analysts, with a mean target of $29 and no low or high target reported. Other cited data show average targets clustered between $28.72 and $30.47; Zacks reports the widest stated range, $25 to $36, an $11 spread, but does not identify the analysts at either end. JPMorgan's stated $30 target is above BofA's $29, though neither snippet dates the change. No dated actions establish the direction of revisions during this week: the target increases reported for JPMorgan and BofA are undated. The spread reflects a debate between sales and pipeline potential, including positive oncology developments, and declining COVID revenue, patent expirations and pressure on future growth.

Rating Actions

1 firm captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
RBC Capital	—	Unrated Raised price target	$25	-16.7%	Jun 10, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

BMO CAPITAL MKT

CANTOR FITZGERA

CITIGROUP

CO FORECST

DAIWA AMERICA

EDWARD JONES

GOLDMAN SACHS

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

ROTHSCHILD REDB

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: PFE
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NYSE

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us.

Key Issues

Bullish view

ELREXFIO met the primary endpoint in a Phase 3 trial, and the FDA expanded the TALZENNA-XTANDI label, adding evidence of pipeline and product progress.

Bearish view

The ELREXFIO report is topline news and says median progression-free survival was not yet reached; the evidence does not quantify the commercial contribution of either development.

Analyst Consensus

See all

Hold

20 analysts

$30

Current

$25

Low

$29

Average

$25

High

Average target implies -3.33% versus the current price.

Earnings History

BeatMissNo estimate

Pfizer, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers